Table 2.

Efficacy results of selpercatinib (LOXO-292) in RET + NSCLC in the primary analysis set and the treatment naive subset.⁶⁰.

Efficacy parameter	Primary analysis set (n = 105)	Treatment naive (n = 39)
Objective response rate (%) Number of patients	68% (95% CI 58–76%) 71/105	85% (95% CI 69–95%) 29/34
CNS objective response rate Number of patients	91% (95% CI 59–100%) 10/11	Not available
Median duration of response Number of events	20.3 months (95% CI 13.8–24.0) 16/69	Not reached 2/22
Progression-free survival Number of events	18.4 months (95% CI 12.9–24.9) 33/105	Not reached 4/34

NSCLC, non-small cell lung cancer; CI, confidence interval; CNS, central nervous system.